Samsung Bioepis' Q1 2025 report shows oncology, ophthalmology, and pegfilgrastim biosimilars have gained significant market share, while immunology, filgrastim, epoetin alfa, and insulin glargine ...

The authors write "Suboxone is the brand name of combination of Buprenorphine and Naloxone, manufactured by Indivior, Inc., ...

On a cold winter day in Illinois, three little pigs are resting in a three-sided shed. They have plenty of space to trot ...

The Certified Naturally Grown label could be more accessible for farmers, but can it actually land with consumers?

PoNS Therapeutic Experience Program (PoNSTEP) study demonstrates durable long-term beneficial effects of PoNS Therapy on gait deficit improvement in people with Multiple Sclerosis-- ...

Healthcare fraud investigations accounted for more than half of the Department of Justice's settlements and judgments in 2024 ...

General Manager and CEO of Junshi Biosciences, Dr. Jianjun ZOU, said, “Toripalimab has made significant strides in its internationalization. As of today, toripalimab has been approved in 35 countries ...

Varon said the reimbursement is useful, but fronting the cash is still a barrier for small ... While some seek out ...

Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) today announces that the supplemental New Drug Application for ORPATHYS® (savolitinib) has been granted approval by the China National Medical Products ...

Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) today announces that the supplemental New Drug Application for ORPATHYS ® (savolitinib) has been granted approval by the China National Medical ...

According to CEO Tim Wentworth, the company has been modifying contracts with insurers who pay for prescriptions and adjusting for high-cost drugs. Meanwhile, the VillageMD sale is moving along.

Mirum Pharmaceuticals Announces Preliminary Unaudited 2024 Net Product Sales and Cash Balance and Provides Corporate Updates ...